Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of intravitreal Lucentis on retinal function in diabetic macular edema
2011-004613-17Phase 4Completed
- Sponsor
- Skåne University Hospital Department of Ophthalmology
- Start
- Sep 2011
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ranibizumab in diabetic macular edema (DME), diabetes mellitus type 1 (T1D) and type 2 diabetes mellitus (T2DM), sponsored by Skåne University Hospital Department of Ophthalmology. Primary endpoint: Effect on retinal cell and macular cell function. Started Sep 2011; status: completed.
02
Drugs
ranibizumab
03
Conditions
diabetic macular edema (DME)diabetes mellitus type 1 (T1D)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2011-004613-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004613-17.